Evidence map›Paper›PMID 24821788›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Tolerance induction in memory CD4 T cells requires two rounds of antigen-specific activation.

Alexandria David, Frances Crawford, Paul Garside, John W Kappler, Philippa Marrack, Megan MacLeod

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Alexandria DavidHoward Hughes Medical Institute, andIntegrated Department of Immunology, National Jewish Health, Denver, CO 80206;
Frances CrawfordHoward Hughes Medical Institute, andIntegrated Department of Immunology, National Jewish Health, Denver, CO 80206;
Paul GarsideCentre for Immunobiology Institute of Infection, Immunity and Inflammation, Glasgow University, Glasgow G12 8TA, United Kingdom; and.
John W KapplerHoward Hughes Medical Institute, andIntegrated Department of Immunology, National Jewish Health, Denver, CO 80206;Department of Medicine,Program in Biomolecular Structure, and.
Philippa MarrackHoward Hughes Medical Institute, andIntegrated Department of Immunology, National Jewish Health, Denver, CO 80206;Department of Medicine,Department of Biochemistry and Molecular Genetics, University of Colorado Denver School of Medicine, Aurora, CO 80045 marrackp@njhealth.org Megan.MacLeod@glasgow.ac.uk.
Megan MacLeodCentre for Immunobiology Institute of Infection, Immunity and Inflammation, Glasgow University, Glasgow G12 8TA, United Kingdom; and marrackp@njhealth.org Megan.MacLeod@glasgow.ac.uk.
National Jewish Health · USHoward Hughes Medical Institute · USUniversity of Colorado Denver · US

Funding

THE REGULATION OF V ALPHA 7 EXPRESSING T CELLSP01AI022295 · NIAID · NATIONAL JEWISH HEALTH · PI CAMBIER, JOHN C · 1985 to 2011
$11.7M
CHARACTERISTICS OF T CELL RECEPTORSR01AI018785 · NIAID · NATIONAL JEWISH HEALTH · PI MARRACK, PHILIPPA C. · 1985 to 2022
$7.3M
CHARACTERISTICS OF T-CELL RECEPTORSR37AI018785 · NIAID · NATIONAL JEWISH HEALTH · PI MARRACK, PHILIPPA C. · 1992 to 2001
$522k
Characteristics of T Cell ReceptorsR56AI018785 · NIAID · NATIONAL JEWISH HEALTH · PI MARRACK, PHILIPPA C. · 2012 to 2012
$410k
Arthritis Research UK 19905Howard Hughes Medical InstituteNIAID NIH HHS AI-18785NIAID NIH HHS AI-22295NIAID NIH HHS P01 AI022295NIAID NIH HHS R01 AI018785NIAID NIH HHS R37 AI018785NIAID NIH HHS R56 AI018785Versus Arthritis 19905Wellcome Trust 085349
6 · The paper itself

Abstract

A major goal for immunotherapy is to tolerize the immune cells that coordinate tissue damage in autoimmune and alloantigen responses. CD4 T cells play a central role in many of these conditions and improved antigen-specific regulation or removal of these cells could revolutionize current treatments. A confounding factor is that little is known about whether and how tolerance is induced in memory CD4 T cells. We used MHC class II tetramers to track and analyze a population of endogenous antigen-specific memory CD4 T cells exposed to soluble peptide in the absence of adjuvant. We found that such memory T cells proliferated and reentered the memory pool apparently unperturbed by the incomplete activation signals provided by the peptide. Upon further restimulation in vivo, CD4 memory T cells that had been previously exposed to peptide proliferated, provided help to primary responding B cells, and migrated to inflamed sites. However, these reactivated memory cells failed to survive. The reduction in T-cell number was marked by low expression of the antiapoptotic molecule B cell lymphoma 2 (Bcl2) and increased expression of activated caspase molecules. Consequently, these cells failed to sustain a delayed-type hypersensitivity response. Moreover, following two separate exposures to soluble antigen, no T-cell recall response and no helper activity for B cells could be detected. These results suggest that the induction of tolerance in memory CD4 T cells is possible but that deletion and permanent removal of the antigen-specific T cells requires reactivation following exposure to the tolerogenic antigen.

Indexed as

Analysis of VarianceAnimalsAntigensAutoimmune DiseasesCaspasesCD4-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryGenes, MHC Class IIImmune ToleranceImmunologic MemoryImmunotherapyLymphocyte ActivationMiceMice, Inbred C57BLAntigensCaspases

Identifiers

PMID24821788
PMCPMC4040609
OpenAlexW2038286032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.